TY - JOUR
T1 - Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine
AU - Gallant, Joel E.
AU - Moore, Richard D.
AU - Richman, Douglas D.
AU - Keruly, Jeanne
AU - Chaisson, Richard E.
AU - Bartlett, John
AU - McAvinue, Sharon
AU - Bryson, Yvonne
AU - Cohen, Helene
AU - Fischl, Margaret
AU - Bolin, Terry
AU - Kessler, Harold
AU - Burrough, Yvonne
AU - Mildvan, Donna
AU - Fox, Alice
AU - Freeman, Ben
AU - Simon, Gary
AU - Grabowy, Kathy Ward
AU - Chernoff, David
AU - Duff, Patricia
AU - Thompson, Sumner
AU - Barrett, Kara
AU - Awe, Robert
AU - Chapman, Ruby
AU - Leonard, Shirley
AU - Turner, Paul
AU - Hawkins, Marge
AU - Murray, Henry
AU - Bowers, Jill
AU - Lane, Clifford
AU - Tilson, Hugh
AU - Andrews, Elizabeth
AU - Smiley, Lynn
N1 - Funding Information:
Received II May 1992; revised 10 July 1992. Presented in part: VIII International Conference on AIDS, Amsterdam. July 1992. Informed consent was obtained from all subjects. and guidelines of the US Department of Health and Human Services and of the authors' institutions were followed in the conduct of the research. Grant support: Burroughs Wellcome (Research Triangle Park. NC); R.D.M. is a Burroughs Wellcome Scholar in pharmacoepidemiology. Reprints or correspondence: Dr. Joel E. Gallant. AIDS Services, Johns Hopkins University School of Medicine. 1830 E. Monument St., Suite 7400, Baltimore. MD 21205. * Study group members are listed after the text.
PY - 1992/12
Y1 - 1992/12
N2 - Data were analyzed from a multicenter observational cohort study of 1002 persons with AIDS or AIDS-related complex (ARC) and total CD4 cell count <0.25 × 109/L treated with zidovudine between April 1987 and April 1988. Cytomegalovirus (CMV) disease developed in 109 patients (10.9%), with a 2-year actuarial risk of 15%. Manifestations included retinitis (93 patients), esophagitis (10), colitis (8), gastritis (1), hepatitis (1), and encephalitis (1). The probability of CMV disease at 2 years for patients with initial counts <0.1 × 109/L was 21.4%, compared with 10.3% for patients with initial counts ⩾0.1 × 109/L (P <.001). By proportional hazards analysis, baseline CD4 cell count <0.1 × 109/L, enrollment diagnosis of AIDS, and homosexuality were significantly associated with subsequently developing CMV disease. Median survival after diagnosis of CMV disease was 173 days, and CMV was an independent predictor of death. CMV contributes to AIDS-related morbidity and mortality. As new anti-CMV drugs become available, prophylaxis should be targeted at individuals with CD4 cell counts <0.1 × 109/L.
AB - Data were analyzed from a multicenter observational cohort study of 1002 persons with AIDS or AIDS-related complex (ARC) and total CD4 cell count <0.25 × 109/L treated with zidovudine between April 1987 and April 1988. Cytomegalovirus (CMV) disease developed in 109 patients (10.9%), with a 2-year actuarial risk of 15%. Manifestations included retinitis (93 patients), esophagitis (10), colitis (8), gastritis (1), hepatitis (1), and encephalitis (1). The probability of CMV disease at 2 years for patients with initial counts <0.1 × 109/L was 21.4%, compared with 10.3% for patients with initial counts ⩾0.1 × 109/L (P <.001). By proportional hazards analysis, baseline CD4 cell count <0.1 × 109/L, enrollment diagnosis of AIDS, and homosexuality were significantly associated with subsequently developing CMV disease. Median survival after diagnosis of CMV disease was 173 days, and CMV was an independent predictor of death. CMV contributes to AIDS-related morbidity and mortality. As new anti-CMV drugs become available, prophylaxis should be targeted at individuals with CD4 cell counts <0.1 × 109/L.
UR - http://www.scopus.com/inward/record.url?scp=0026479981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026479981&partnerID=8YFLogxK
U2 - 10.1093/infdis/166.6.1223
DO - 10.1093/infdis/166.6.1223
M3 - Article
C2 - 1358986
AN - SCOPUS:0026479981
SN - 0022-1899
VL - 166
SP - 1223
EP - 1227
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 6
ER -